The Quantellect read.As of Nov 19, 2026, 16 active firms cover Wave Life Sciences Ltd: 15 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $10.00 to $43.00 (about 4.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $18.20 sits 556% above the current $2.77. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 13 to 15 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.35 next quarter toward $-1.17 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 active firms
Buy
Strong Buy00%
Buy1594%
Neutral16%
Sell00%
Strong Sell00%
Based on 16 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$18.20
+555.9% upside
Average target across 10 active firms as of Nov 19, 2026 vs $2.78 current
Highest Target$43.00
Average Target$18.20
Lowest Target$10.00
Detailed analyst forecasts for WVE
Showing 1–11 of 11 named analysts shown · 16 active firms in the rating projection
As of Nov 19, 2026, 15 of 16 active firms rate WVE a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
WVE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.35
Range $-0.41 – $-0.26 · 8 analysts · +168% YoY
Next period, 8 analysts expect Wave Life Sciences Ltd to earn $-0.35 a share (range $-0.41 – $-0.26), versus $-0.13 a year earlier. Full-year consensus is $-1.10, growing to $-1.17 the year after.
REVENUE · NEXT QUARTER
$7.7M
Range $0 – $23.8M · 8 analysts · -80% YoY
Revenue is expected to reach $7.7M (range $0 – $23.8M), -79.8% year-over-year. Full-year consensus is $63.5M, rising to $35.1M next year.
Top analysts covering Wave Life Sciences Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on WVE.
#1
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$13.00+368.5% to target
Overall win rate
45%
+ Follow
#2
Luca Issi
RBC Capital · Rank #76
Buy
$15.00+440.5% to target
Overall win rate
49%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$18.00+548.6% to target
Overall win rate
43%
+ Follow
#4
Joseph Schwartz
Leerink Partners · Rank #242
Buy
$25.00+800.9% to target
Overall win rate
36%
+ Follow
#5
SS
Samantha Semenkow
Citigroup · Rank #333
Buy
$19.00+584.7% to target
Overall win rate
41%
+ Follow
WVE stock forecast FAQ
What is WVE's average 12-month price target?+
The 10 active firms with a live target average $18.20 for Wave Life Sciences Ltd over the next 12 months, ranging from a $43.00 high to a $10.00 low, as of Nov 19, 2026.
Is WVE stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 16 active firms as of Nov 19, 2026, 15 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for WVE?+
The Street-high target is $43.00 (Canaccord Genuity), and the Street-low is $10.00 (Ladenburg Thalmann). The average of all 10 active-firm targets is $18.20.
How many active Wall Street firms cover WVE?+
16 active firms have a recognized rating on Wave Life Sciences Ltd as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering WVE?+
Among analysts who currently cover WVE, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #73). Their current call is Buy with a $13.00 target.
What is Wave Life Sciences Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.35 per share (range $-0.41 – $-0.26) across 8 analysts. Full-year EPS is projected at $-1.10, rising to $-1.17 the following year.
How much revenue is Wave Life Sciences Ltd expected to report next quarter?+
Consensus revenue is $7.7M (range $0 – $23.8M). Full-year revenue is projected at $63.5M, growing to $35.1M next year.
Have analysts been upgrading or downgrading WVE lately?+
As of Nov 19, 2026, 15 of 16 active firms rate WVE a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their WVE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.